Glycopyrrolate-Inhaled

• COPD Maintenance Treatment
• Chronic Bronchitis
• Emphysema
• LAMA Bronchodilator Therapy

Glycopyrrolate (glycopyrronium) for inhalation is a long-acting muscarinic antagonist (LAMA) bronchodilator used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This inhaled anticholinergic provides sustained bronchodilation with twice-daily or once-daily dosing depending on the formulation.

Mechanism of Action

Glycopyrrolate is a quaternary ammonium compound that acts as a competitive antagonist of muscarinic (M) receptors, particularly M3 receptors in airway smooth muscle. In COPD, excessive parasympathetic tone leads to bronchoconstriction via acetylcholine-mediated activation of M3 receptors on bronchial smooth muscle. By blocking M3 receptors, glycopyrrolate prevents acetylcholine-induced bronchoconstriction, resulting in bronchodilation. The quaternary structure limits systemic absorption and CNS penetration, reducing systemic anticholinergic effects. The medication has long receptor binding duration, providing sustained bronchodilation.

Available Formulations

Inhaled glycopyrrolate is available in several formulations: nebulizer solution (Lonhala Magnair: 25 mcg/mL in single-dose vials), dry powder inhaler (Seebri Neohaler: 15.6 mcg/capsule for inhalation), and pressurized metered-dose inhaler. It is also available in fixed-dose combinations with formoterol (Bevespi Aerosphere) and with indacaterol (Utibron Neohaler). Each formulation has specific device instructions.

Medical Uses

Inhaled glycopyrrolate is FDA-approved for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not indicated for relief of acute bronchospasm, treatment of acute exacerbations, or treatment of asthma. Clinical trials demonstrated improvements in lung function (FEV1), COPD symptoms, and quality of life measures.

Dosing Guidelines

For the nebulizer solution (Lonhala Magnair), the dose is 25 mcg (one vial) inhaled twice daily via the specific nebulizer system. For the dry powder inhaler (Seebri Neohaler), the dose is one 15.6 mcg capsule inhaled twice daily using the Neohaler device. Capsules should not be swallowed. The medication should be taken at approximately the same times each day. Only use with the designated delivery device for each product.

Important Safety Information

Glycopyrrolate is contraindicated in patients with severe hypersensitivity to milk proteins or glycopyrrolate. As with all inhaled anticholinergics, it should not be used for relief of acute symptoms or acute bronchospasm (a rescue inhaler should be available). Use with caution in patients with narrow-angle glaucoma, urinary retention, or prostatic hyperplasia. Paradoxical bronchospasm may occur; discontinue if this occurs. Worsening of narrow-angle glaucoma and urinary retention have been reported.

Drug Interactions

Concurrent use with other anticholinergic-containing medications may increase anticholinergic adverse effects; avoid combination if possible. No significant interactions have been observed with beta-agonists, corticosteroids, or other commonly used COPD medications. Glycopyrrolate is minimally metabolized and does not significantly interact with cytochrome P450 enzymes.

Special Populations

There are no adequate studies in pregnant women. Animal studies showed some effects at high doses. Use during pregnancy only if clearly needed. It is unknown whether inhaled glycopyrrolate is excreted in human breast milk; consider the developmental benefits of breastfeeding. Safety and efficacy have not been established in pediatric patients. Clinical trials included patients up to 80 years; no overall differences were observed in elderly patients, though increased sensitivity is possible. No dose adjustment is needed for renal or hepatic impairment based on the inhaled route and minimal systemic absorption.